{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"response was assessed by the RECIST criteria (version 1.0). Per those criteria, progression is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","groups":[{"description":"cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks","id":"OG000","title":"Cisplatin, Pemetrexed, Bevacizumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"from time of enrollment to time of best response or death from any cause, whichever came first up to 100 months","title":"Response Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}